CA2569687A1 - Procede de modulation de l'activite cellulaire faisant intervenir une sphingosine kinase, agents utilises a cet effet et variantes de sphingosine kinase - Google Patents

Procede de modulation de l'activite cellulaire faisant intervenir une sphingosine kinase, agents utilises a cet effet et variantes de sphingosine kinase Download PDF

Info

Publication number
CA2569687A1
CA2569687A1 CA002569687A CA2569687A CA2569687A1 CA 2569687 A1 CA2569687 A1 CA 2569687A1 CA 002569687 A CA002569687 A CA 002569687A CA 2569687 A CA2569687 A CA 2569687A CA 2569687 A1 CA2569687 A1 CA 2569687A1
Authority
CA
Canada
Prior art keywords
sphingosine kinase
localisation
cell
cell membrane
intracellular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002569687A
Other languages
English (en)
Inventor
Stuart M. Pitson
Mathew Alexander Vadas
Pu Xia
Paul A. Moretti
Tamara Leclercq
Catherine Sutherland
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medvet Science Pty Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2004903249A external-priority patent/AU2004903249A0/en
Application filed by Individual filed Critical Individual
Publication of CA2569687A1 publication Critical patent/CA2569687A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
CA002569687A 2004-06-15 2005-06-15 Procede de modulation de l'activite cellulaire faisant intervenir une sphingosine kinase, agents utilises a cet effet et variantes de sphingosine kinase Abandoned CA2569687A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2004903249A AU2004903249A0 (en) 2004-06-15 A method of modulating cellular activity and agents useful for same
AU2004903249 2004-06-15
PCT/AU2005/000856 WO2005123115A1 (fr) 2004-06-15 2005-06-15 Procede de modulation de l'activite cellulaire faisant intervenir une sphingosine kinase, agents utilises a cet effet et variantes de sphingosine kinase

Publications (1)

Publication Number Publication Date
CA2569687A1 true CA2569687A1 (fr) 2005-12-29

Family

ID=35509458

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002569687A Abandoned CA2569687A1 (fr) 2004-06-15 2005-06-15 Procede de modulation de l'activite cellulaire faisant intervenir une sphingosine kinase, agents utilises a cet effet et variantes de sphingosine kinase

Country Status (5)

Country Link
EP (1) EP1765384A4 (fr)
JP (1) JP2008502604A (fr)
CA (1) CA2569687A1 (fr)
MX (1) MXPA06014888A (fr)
WO (1) WO2005123115A1 (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO900297A0 (en) * 1997-09-08 1997-10-02 Medvet Science Pty. Ltd. A method of modulating cellular activity
AUPQ744700A0 (en) * 2000-05-11 2000-06-01 Medvet Science Pty. Ltd. A method of treatment and agents useful for same
US20050100547A1 (en) * 2001-06-07 2005-05-12 Pu Xia Etal Sphingosine kinase interacts with traf2 and modulates tumor necrosis factor-induced cellular activity
CA2480661A1 (fr) * 2002-03-28 2003-10-09 Medvet Science Pty. Ltd. Methode de modulation d'activite cellulaire

Also Published As

Publication number Publication date
WO2005123115A1 (fr) 2005-12-29
WO2005123115A8 (fr) 2006-04-20
EP1765384A4 (fr) 2009-07-08
JP2008502604A (ja) 2008-01-31
MXPA06014888A (es) 2007-03-21
EP1765384A1 (fr) 2007-03-28

Similar Documents

Publication Publication Date Title
US6730480B1 (en) Sphingosine kinase enzyme
AU2001256001B2 (en) Sphingosine kinase and uses thereof
NZ529983A (en) Sphingosine kinase interacts with TRAF2 and modulates tumor necrosis factor-induced cellular activity
CA2612644A1 (fr) Modulation de la signalisation de la sphingosine kinase
AU2009201639A1 (en) A method of modulating cellular activity
AU2005253643B2 (en) Methods of modulating cellular activity involving sphingosine kinase and agents for same, and sphingosine kinase variants
CA2612773A1 (fr) Modulation de la signalisation de la sphingosine kinase
CA2569687A1 (fr) Procede de modulation de l'activite cellulaire faisant intervenir une sphingosine kinase, agents utilises a cet effet et variantes de sphingosine kinase
CA2595469A1 (fr) Procede de traitement d'un dommage cellulaire
AU2006261583A1 (en) Modulation of sphingosine kinase signalling
NZ523343A (en) Novel therapeutic molecular variants and uses thereof
AU2006261584A1 (en) Modulation of sphingosine kinase signalling
AU2001265699B2 (en) Novel therapeutic molecular variants and uses thereof
AU2002304973B2 (en) Sphingosine kinase interacts with TRAF2 and modulates tumor necrosis factor-induced cellular activity
AU780746B2 (en) Sphingosine kinase enzyme
Xia 2. An isolated polynucleotide according to claim 1, the polynucleotide comprising a sequence at least 95% identical to SEQ ID NO: 1. 3. An isolated polynucleotide sequence that hybridizes to the nucleotide sequence of claim 2 stringency conditions of about 65 C C. and about 50% v/v formamide and about 0.15 M salt. 4. An isolated polynucleotide according to claim 1, the polynucleotide encoding a polypeptide having the sequence of SEQ ID NO: 2. 5. An isolated polynucleotide according to claim 1, the polynucleotide comprising the sequence of SEQ ID NO: 1. 6. An expression system comprising a polynucleotide according to claim 1.
AU2006207818A1 (en) A method of treating cellular damage
ZA200300214B (en) Novel therapeutic molecular variants and uses thereof.
AU2001265699A1 (en) Novel therapeutic molecular variants and uses thereof
AU2002304973A1 (en) Sphingosine kinase interacts with TRAF2 and modulates tumor necrosis factor-induced cellular activity
AU2006261582A1 (en) Modulation of EGFR signalling by modulation of sphingosine kinase signalling

Legal Events

Date Code Title Description
FZDE Dead